Briacell Therapeutics Corp Stock Net Income
| BCT Stock | 15.22 4.58 43.05% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Briacell Therapeutics' long-term financial health and intrinsic value.
| Last Reported | Projected for Next Year | ||
| Net Loss | -23.9 M | -22.7 M | |
| Net Loss | -23.7 M | -22.5 M | |
| Net Loss | -4.4 M | -4.7 M | |
| Net Loss | (77.63) | (81.51) | |
| Net Income Per E B T | 1.14 | 1.08 |
Briacell | Net Income |
Briacell Therapeutics Corp Company Net Income Analysis
Briacell Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Briacell Therapeutics Net Income | (26.56 M) |
Most of Briacell Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Briacell Therapeutics Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Briacell Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Briacell Therapeutics is extremely important. It helps to project a fair market value of Briacell Stock properly, considering its historical fundamentals such as Net Income. Since Briacell Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Briacell Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Briacell Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Briacell Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Briacell Therapeutics Corp reported net income of (26.56 Million). This is 107.78% lower than that of the Biotechnology sector and 137.91% lower than that of the Health Care industry. The net income for all Canada stocks is 104.65% higher than that of the company.
Briacell Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Briacell Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Briacell Therapeutics could also be used in its relative valuation, which is a method of valuing Briacell Therapeutics by comparing valuation metrics of similar companies.Briacell Therapeutics is currently under evaluation in net income category among its peers.
Briacell Fundamentals
| Return On Equity | -4.44 | ||||
| Return On Asset | -1.62 | ||||
| Current Valuation | 5.88 M | ||||
| Shares Outstanding | 1.88 M | ||||
| Shares Owned By Insiders | 2.33 % | ||||
| Shares Owned By Institutions | 4.19 % | ||||
| Number Of Shares Shorted | 6.96 K | ||||
| Price To Book | 1.44 X | ||||
| EBITDA | (36.63 M) | ||||
| Net Income | (26.56 M) | ||||
| Total Debt | 4.32 M | ||||
| Book Value Per Share | 7.37 X | ||||
| Cash Flow From Operations | (28.17 M) | ||||
| Short Ratio | 0.96 X | ||||
| Earnings Per Share | (47.13) X | ||||
| Target Price | 20.0 | ||||
| Beta | 1.91 | ||||
| Market Capitalization | 20.04 M | ||||
| Total Asset | 21.65 M | ||||
| Retained Earnings | (154.51 M) | ||||
| Working Capital | (3.81 M) | ||||
| Net Asset | 21.65 M |
About Briacell Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Briacell Therapeutics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Briacell Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Briacell Therapeutics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Briacell Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Briacell Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Briacell Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Briacell Stock
| 0.68 | FFH-PI | Fairfax Financial | PairCorr |
| 0.68 | AX-UN | Artis Real Estate | PairCorr |
| 0.57 | FFH | Fairfax Financial | PairCorr |
| 0.55 | KTO | K2 Gold | PairCorr |
| 0.54 | VM | Voyageur Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Briacell Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Briacell Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Briacell Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Briacell Therapeutics Corp to buy it.
The correlation of Briacell Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Briacell Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Briacell Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Briacell Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Briacell Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.